[firasd]

Yes, the customer-friendly blood testing in India would be incredibly "disruptive" to American lab tests. Not only does the US have different costs and regulations but the medical industry is based on extracting money from insurance companies so every process is a bit occluded.

That said, Theranos is still on the hook because a business model innovation would probably not justify their valuation and PR compared to a tech innovation.

[adevine]

If it were just a business model innovation, Theranos would rightly be worth nothing, because they wouldn't bring anything to the table. CVS or Walgreen's have all the assets that would be worth anything in this situation.